Finkbiner K L, Ernst T F
Cancer Pract. 1993 Nov-Dec;1(4):295-304.
Neutropenia is one of the major dose-limiting toxicities of cancer chemotherapy. Since the 1960s, dramatic changes have occurred in its epidemiology, microbiology, and treatment. This article highlights these important changes; reviews the history and current practice of antibiotic, antifungal, and antiviral therapy; and looks toward future therapy using colony-stimulating factors (CSFs) for the infectious complications in the febrile neutropenic cancer patient.
中性粒细胞减少是癌症化疗的主要剂量限制性毒性之一。自20世纪60年代以来，其流行病学、微生物学及治疗方面都发生了显著变化。本文着重介绍这些重要变化；回顾抗生素、抗真菌药及抗病毒治疗的历史与当前实践；并展望使用集落刺激因子（CSF）治疗发热性中性粒细胞减少癌症患者感染并发症的未来疗法。
